soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025

soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 results Reduces Events in People with Type 2 Oral Semaglutide and Cardiovascular Outcomes

Name: soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 results Reduces Events in People with Type 2 Oral Semaglutide and Cardiovascular Outcomes
Brand: kisobran.org
SKU: 8208032741
Price: 22.32 USD
Availability: InStock
Rating: 4.4671 (26 reviews)

SKU: 8208032741

4.5

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 7 - Aug 12

Description

Steady state is reached in 4 to 5 weeks of weekly dosing at each dose level -- which is why the standard titration holds each dose for 4 weeks before escalating

Glucose Regulation Studies: Investigated for its effects on glucose pathways, including insulin secretion and regulation in metabolic dysregulation models

Specifically, tirzepatide was associated with a 50% reduced risk of POAG, 26% reduced risk of OHT and 41% reduced risk of requiring new glaucoma treatment